Asia Pacific Acne Drugs Market

APAC Acne Drugs Market Size (2024 to 2029)

The acne drugs market size in Asia-Pacific was worth USD 2.11 billion in 2023. The regional market is further projected to grow at a CAGR of 6.8% from 2024 to 2029 and be worth USD 3.13 billion by 2029 from USD 2.25 billion in 2024.

Factors such as Lack of sleep, high intake of smoking and alcohol consumption, misusage of drugs, and emotional and work-related stress are propelling the acne drugs market in the APAC region. According to the Global Burden of Disease Study, acne vulgaris affects nearly 85% of people aged 12-25 years. The increasing demand for minimally invasive cosmetic treatment procedures is mounting remarkably. Escalating demand for brisk treatments and swift results are projected to drive the need for equipment-based procedures like laser treatments. In addition, rising awareness of acne issues among the single and consciousness regarding the present and upcoming treatments, advanced technologies, and augmenting per capita income motivating the customers to spend more on personal care are anticipated to boost the demand for acne drugs in this region.

The usability of alternatives for acne drugs and therapies served by local players, lack of experienced and skilled dermatologists is predicted to restrain the market growth. In addition, the rising demand for self-medication without a doctor’s prescription and the significance of substitute therapies for nursing acne have been obstructing the sales of branded acne products.

REGIONAL ANALYSIS

The Asia-Pacific market for acne drugs is anticipated to have rapid growth in the global market in terms of revenue because of common skin diseases and conditions like abnormal hormone growth, high intake of carbohydrates, massive consumption of junk food, and excessive intake of fat creating foods.

The Indian acne drugs market is anticipated to expand at 9.2% CAGR during the forecast period. There are around 200-300 million acne sufferers, finally aiding the market growth in India. In addition, the market is attributed to the growing demand of the population in expending on facial.

The Chinese acne drugs market is expected to lead the APAC market over the forecast period. Increase in many product launches, growing demand for acne therapies, and uplift in healthcare expenses and awareness relevant to newly enhanced therapies that can substitute conventional acne treatment in this region. Rising behavior and unhealthy eating habits, and increasing income bolstered market growth during the analysis period. Moreover, the accessibility of experienced and knowledgeable dermatologists involving the patients virtually in treatment design is anticipated to add fuel to the development of acne treatment in terms of income. India and China are expected to have rapid growth in the region.

KEY PLAYERS IN THE ASIA-PACIFIC ACNE DRUGS MARKET

Some of the major companies dominating the Asia Pacific acne drugs market by their products and services include Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Amgen, Inc., Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Mylan N.V., and Daiichi Sankyo Company, Ltd.

DETAILED SEGMENTATION OF THE ASIA-PACIFIC ACNE DRUGS MARKET INCLUDED IN THIS REPORT

This research report on the Asia Pacific Acne Drugs Market has been segmented & sub-segmented into the following categories

By Type 

• OTC drugs
• Prescription drugs

By Route of Administration 

• Topical
• Oral

By Drug Class 

• Antibiotics
• Anti-Inflammatory Drugs
• Anti-Microbial
• Combination Drugs
• Hormonal Agents
• Oral Retinoid
• Topical Retinoid

By Country 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC